Amundi and its subsidiary Amundi Asset Management filed Amendment No. 13 to a beneficial ownership statement with the SEC on October 26, 2026, reporting aggregate beneficial ownership of 68,832,052 shares of Sanofi, representing 5.70% of the class, as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Amundi reported 68,832,052 shares of Sanofi beneficially owned, equal to 5.70% of the class.
  • Shared voting power: Amundi holds shared voting power over 34,587,207 shares, with zero sole voting power.
  • Shared dispositive power: Shared power to dispose covers 34,244,845 shares; sole dispositive power is reported as zero.
  • FCPE carve-out: Voting rights on 30,319,386 shares are exercised by the supervisory board of a French employee shareholding vehicle, not by Amundi.
  • Amendment number: This is the 13th amendment to the filing, triggered by an event dated September 30, 2026.
  • Reporting persons: Both Amundi and Amundi Asset Management are organized under the laws of France and share the same address at 91-93 boulevard Pasteur, 75015 Paris.

Amundi's Reported Position in Sanofi and the Employee Fund Structure

According to the filing, Amundi and Amundi Asset Management jointly report beneficial ownership of 68,832,052 shares of Sanofi (NASDAQ:SNY), a global pharmaceutical company headquartered at 46 avenue de la Grande Armee, 75017 Paris. The securities covered include common stock, American Depositary Receipts, and convertible bonds, identified by CUSIP number 80105N105. Both reporting persons are classified as parent holding companies (type "HC") under the applicable SEC rules.

A notable element of the disclosure concerns voting rights. The filing states that Amundi "does not have voting rights on 30,319,386 shares which are held through a FCPE (Fonds Commun de Placement d'Enterprise, an investment vehicle established under French law), solely dedicated to Sanofi group's employees shareholding." According to the filing, the voting rights on those shares are exercised by the supervisory board of the FCPE, where employee representatives hold the majority, not by Amundi. The FCPE was created at the request of Sanofi, and employees participate through Sanofi stock purchase plans.

The filing also lists fourteen subsidiaries through which Amundi Asset Management holds the reported securities, including Amundi Austria GmbH, Amundi Ireland Limited, Amundi Japan Ltd., Amundi SGR S.p.A., CPR Asset Management, KBI Global Investors Ltd, and Sabadell Asset Management, S.A S.G.I.I.C, among others. Amundi certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Amundi and Amundi Asset Management, both organized in France, filed Amendment No. 13 to report 68,832,052 Sanofi shares beneficially owned as of September 30, 2026, amounting to 5.70% of the class, with a substantial portion of associated voting rights held by a French employee investment vehicle rather than by Amundi itself.